Company: HCTI
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026218
Chunk: 548

Company: Healthcare Triangle, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 548
---
 Debt discount already recorded in the financial statements. 

    6.
    The management concluded that our limited resources prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties. Further we have limited specific technical accountants and therefore it is difficult for us to effectively segregate accounting duties and have proper financial reporting, which creates a material weakness in our internal controls over financial reporting.

Accordingly, management concluded there was a
material weakness in our internal control over financial reporting at December 31, 2024.

Changes in Internal Controls over Financial Reporting

There were no changes in our internal control
over financial reporting during the twelve months ended December 31, 2024, that have materially affected, or are reasonably likely to
materially affect, our internal control over financial reporting.

Item 9B. Other Information

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent
Inspections.

None.

47

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The following are our executive officers and directors and their respective
ages and positions as of March 31, 2025.

    Name
     
    Age
     
    Position
  
    Dave Rosa  
     
    59
     
    Chairman of the Board of Directors.
  
    Thyagarajan Ramachandran
     
    49
     
    Chief Financial Officer
  
    Sujatha Ramesh*
     
    54
     
    Chief Operating Officer
  
    Shibu Kizhakevilayil
     
    52
     
    Head of M&A and Director
  
    Ronald McClurg
     
    64
     
    Director
  
    Jainal Bhuiyan
     
    42
     
    Director

●Appointed
effectively on March 18, 2025.

Dave Rosa

Mr. Rosa has served as a member of our board of
directors since August 2021. Since 2016, Mr. Rosa has been and currently is President and CEO of NeuroOne Medical Technologies (NMTC:
Nasdaq), a publicly traded company on the Nasdaq. He also serves on the boards of Biotricity (BTCY: OTC), a publicly traded company on
the Over the Counter (OTC) platform, where he currently serves as compensation committee chairman and Neuro Event Labs, a privately held
company in Finland, where he